
OpenAnesthesia and the APSF: Achieving Safe and Quality Anesthesia Care with Education Innovation
New! APSF's Podcast
Medical Safety Principles
New PAINTS episode with Drs. Morrissey and Nash
Psychological Safety
New PAINTS episode with Dr. Joseph Sisk
May 2025 POCUS Case of the Month: Lung Ultrasound
Join Dr. Eric Heinz for the latest episode of this vodcast series!
Transitioning to Inclusivity in OB Anesthesia
Latest episode of the Fellows Webinar Series
Check out the latest OpenAnesthesia Summaries!
More than 400 mini-reviews on high-yield topics in anesthesiology, critical care, and perioperative medicine.
Question of the Day
A 66-year-old woman with degenerative scoliosis receives methadone after thoracolumbar spinal fusion. Antagonism at which of the following sites explains the analgesic effects of methadone?
Explanation
Methadone is a long-acting opioid that has a typical elimination half-life between 15 to 60 hours with a mean of around 22 hours. Metabolism rates vary greatly between individuals, up to a factor of 100, ranging from as few as 4 hours to as many as 130 hours. This variability is apparently due to the variable expression of CYP3A4, CYP2B6, and CYP2D6, the effects of enzyme induction and inhibition by other drugs, as well as environmental factors. Methadone is a racemic mixture of the L- and D- isomers. The opioid activity of racemic methadone results almost entirely the result of L-methadone whereas D-methadone acts as an NMDA antagonist. The likely involvement of NMDA systems in the mechanism of opioid tolerance and hyperalgesia suggests that the NMDA receptor antagonists may be useful for the treatment of postoperative pain. Methadone is unique in that it is an opioid that can attenuate (or even prevent) opioid tolerance.
References:
Chronic Pain: Methadone Gottschalk A, Durieux ME, Nemergut EC. Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery. Anesth Analg. 2011;112(1):218-223. doi:10.1213/ANE.0b013e3181d8a095 Chhabra S, Bull J. Methadone. Am J Hosp Palliat Care. 2008;25(2):146-150. doi:10.1177/1049909107312597OA Series: June 2025
14:47
APSF Podcast
OpenAnesthesia and the APSF: Achieving Safe and Quality Anesthesia Care with Education InnovationAllison Bechtel, MD, University of Virginia, Charlottesville, VA
Copy link
18:06
OA-POCUS Case of the Month
May 2025 POCUS Case of the Month: Lung UltrasoundEric R. Heinz, MD, PhD, George Washington University, Washington, DC, Section Editor: Yuriy Bronshteyn
Copy link
46:34
OA-SOAP Fellows Webinar Series
Transitioning to Inclusivity in OB AnesthesiaHilary MacCormick, MD, FRCPC, Dalhousie University, Halifax, NS, Canada, James Damron, MD, University of Kentucky, Lexington, KY
Copy link
14:43
PAINTS
Medical Safety PrinciplesMegan Nash, DO, Children’s Hospital Colorado, Aurora, CO, Tyler P. Morrissey, MD, University of Colorado, Aurora, CO
Copy link
14:02
PAINTS
Psychological Safety at WorkJoseph M. Sisk, MD, FAAP, University of North Carolina, Chapel Hill, NC
Copy link